ArtVentive Medical's EOS Device Receives FDA Clearance

December 4, 2014—ArtVentive Medical Group, Inc. announced that it has received US Food and Drug Administration (FDA) clearance for its EOS endoluminal occlusion system for use in the peripheral vasculature to provide immediate, complete, and total occlusion in arterial and venous settings.

The catheter-based, self-expandable ArtVentive EOS facilitates permanent or temporary occlusion of peripheral lumens and is designed to serve as a safe and reliable alternative to major surgery in certain cases. The device serves as a platform for several major clinical areas, including peripheral and neurological vascular disorders, women’s health, interventional cardiology, as well as pulmonary and interventional oncology procedures, stated the company.

In ArtVentive’s press release, Anthony Venbrux, MD, commented, “I see the EOS device as a potential game changer for physicians and their patients. In my experience with the device, it has shown immediate and complete vascular occlusion upon deployment. The use of this new endovascular technology assures the operator that they have stopped blood flow at the treatment site. This creates an opportunity for shorter procedure times and less radiation exposure to patients and staff in addition to lower medical costs.” Dr. Venbrux is an interventional radiologist at The George Washington University Hospital in Washington, DC.